BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 1999

View Archived Issues

Company Profile: Allelix

Read More

The relationship among ERT, cardiovascular disease and cancer

Read More

Amylin signs letter of intent for sale of Cabrillo division

Read More

Centocor: Q4 1998 highlights

Read More

ERT gel available in Canada

Read More

Biogen and Inhale enter agreement for pulmonary delivery of Avonex

Read More

Glaxo Wellcome issues new R&D pipeline

Read More

Activase for acute management of stroke approved in Canada

Read More

Noven, Novartis and Vivelle Ventures to join in promoting osteoporosis nasal spray

Read More

Alpharma and Ascent enter strategic alliance

Read More

Licensing partner sought for development of prohibitin gene-based cancer Rx, Dx

Read More

Available for licensing from OMRF: diagnostic and therapeutic agents for spondyloarthropathies

Read More

Polyol anti-Helicobacter pylori agents, compositions and use claimed by Takeda

Read More

Structurally novel antiinflammatory/antiallergic agents in the Astra pipeline

Read More

SangStat's Thymoglobulin launched in U.S.

Read More

Janssen patents structurally distinct gastric prokinetic agents

Read More

Peptidomimetic aspartyl protease inhibitors from Pharmacopeia for AD and malaria

Read More

Dual 5-HT1A antagonists and 5-HT reuptake inhibitors emerge from research at Vita-Invest

Read More

U.S. patent providing improved gene delivery vectors issued to GenVec

Read More

Patent covers Millennium process for identifying antimicrobial drug targets

Read More

FDA accepts NDA filing for Evacet

Read More

Antihypertensive effects of bradykinin agonist FR-190997 evaluated in animals

Read More

Renal protective effects of azelnidipine involve inhibition of AGE production

Read More

Zeneca seeks European approval for Zomig formulation using OraSolv technology

Read More

Liposome initiates phase I clinical trial of TLC-ELL-12

Read More

Ceresine shows positive results in phase II trial in stroke patients

Read More

FDA permits initiation of GlycoDesign's phase I/II study of GD0039 as chemoprotective agent

Read More

Serevent now available in Canada as a treatment for chronic obstructive pulmonary disease

Read More

AVI BioPharma presents data from preclinical study of Resten-NG in restenosis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing